[Stem cell mobilization with plerixafor in pediatric solid tumors patients: a single-center study]

Area of Science:

• Hematology
• Pediatric Oncology
• Stem Cell Transplantation

Background:

• Autologous peripheral blood stem cell (PBSC) collection is often difficult in pediatric patients with solid tumors after chemotherapy.
• Plerixafor is a hematopoietic stem cell mobilizing agent used in these challenging cases.
• Limited reports exist on plerixafor use in Japan for pediatric patients.

Purpose of the Study:

• To evaluate the efficacy and safety of plerixafor for stem cell mobilization in pediatric patients with solid tumors.
• To assess the feasibility of achieving target CD34-positive cell doses for autologous transplantation.
• To document adverse events associated with plerixafor use in this population.

Main Methods:

• A single-center retrospective observational study was conducted.
• Eight pediatric patients with solid tumors underwent nine plerixafor mobilization attempts between 2015 and 2024.
• Data on cell collection, transplantation success, and adverse events were analyzed.

Main Results:

• The median collected CD34-positive cell count was 10.8×10^6/kg.
• Successful achievement of the target cell dose for autologous transplantation was observed in all cases.
• Adverse events were mild and transient, including headache, elevated liver enzymes, and diarrhea; no severe events occurred.

Conclusions:

• Plerixafor demonstrated efficacy and good tolerability in pediatric patients with solid tumors.
• Its effectiveness was consistent across newly diagnosed and relapsed disease statuses.
• Plerixafor represents a valuable option for stem cell mobilization in Japanese pediatric transplant settings.